Gilead, cancer test makers up after U.S. top court ruling on preventative coverage

Shares of Gilead Sciences GILD.O rise 3.1% to $110.69 in morning trade

U.S. Supreme Court rules in favor of Obamacare preventive care task force

The task force helps guarantee that health insurers cover preventive care such as cancer screenings at no cost to patients

Cancer test makers such as Exact Sciences EXAS.O up 4.8% at $54.32 and Guardant Health GH.O up 1.6%

Labcorp Holdings LH.N, which offers cancer tests, is up 1.5% at $260.73

The justices in a 6-3 decision reversed the lower court's ruling on Friday which will likely help in allaying investor fears on insurance coverage for PrEP or pre-exposure prophylaxis drugs

PrEP drugs are approved in the U.S. to prevent HIV infection which are made by Gilead and by ViiV Healthcare, a joint venture of GSK GSK.L, Pfizer PFE.N and Shionogi 4507.T

Including session's move, GILD up 17.3%, EXAS down 3.9%, LH up 13.5%, GH up 65% YTD